• OPEN AN ACCOUNT
Indian Indices
Nifty
25,195.80 113.50
(0.45%)
Sensex
82,570.91 317.45
( 0.39%)
Bank Nifty
57,006.65 241.30
( 0.43%)
Nifty IT
37,424.60 150.90
( 0.40%)
Global Indices
Nasdaq
44,472.11 79.59
(0.18%)
Dow Jones
6,289.33 8.58
(0.14%)
Hang Seng
39,646.81 187.19
(0.47%)
Nikkei 225
8,938.32 -59.74
(-0.66%)
Forex
USD-INR
85.82 0.14
(0.17%)
EUR-INR
100.30 -0.06
(-0.06%)
GBP-INR
115.75 -0.66
(-0.57%)
JPY-INR
0.58 0.00
(-0.62%)

EQUITY - MARKET SCREENER

Sun Pharmaceutical Industries Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524715
INE044A01036
101.444166
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SUNPHARMA
94.39
403580.14
EPS(TTM)
Face Value()
Div & Yield %
17.82
1
0.95
 

sun pharmaceutical industries ltd
Sun Pharma settles litigation related to LEQSELVI™ with Incyte
Jul 14,2025

 Sun Pharmaceutical Industries  announced that further to its intimation dated 10 April 2025, Sun and Incyte Corporation (Incyte) have entered into a settlement and license agreement regarding litigation related to LEQSELVI™ (deuruxolitinib).

Under the terms of agreement, the parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation.

As a part of agreement, Incyte has granted to Sun a limited, non-exclusive license to U.S. Patent Nos. 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S.

Sun will pay to Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license. Other specific terms of the settlement and license agreement are confidential.